These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15584768)

  • 1. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in acute ischaemic stroke: scientific rationale and available evidence.
    Pancioli AM; Brott TG
    CNS Drugs; 2004; 18(14):981-8. PubMed ID: 15584768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke.
    Lapchak PA; Araujo DM
    Am J Cardiovasc Drugs; 2003; 3(2):87-94. PubMed ID: 14727935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa antagonists for acute ischemic stroke.
    Bogousslavsky J; Leclerc JR
    Neurology; 2001; 57(5 Suppl 2):S53-7. PubMed ID: 11552056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    Ciccone A; Abraha I; Santilli I
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005208. PubMed ID: 17054247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet glycoprotein IIb/IIIa blockade in acute ischemic stroke.
    Bogousslavsky J; Leclerc JR
    Cerebrovasc Dis; 2001; 11(4):287-93. PubMed ID: 11385206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.
    Bogousslavsky J; Paciaroni M; Gallai V
    Clin Exp Hypertens; 2002; 24(7-8):603-10. PubMed ID: 12450235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care.
    Hankey GJ
    Cerebrovasc Dis; 2004; 17 Suppl 3():11-6. PubMed ID: 14730253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotics and thrombolytics in stroke.
    Mousa SA; Iqbal O; Fareed J
    Curr Opin Investig Drugs; 2002 Jun; 3(6):878-85. PubMed ID: 12137407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.
    Stringer KA
    Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and benefits of glycoprotein IIb/IIIa antagonists in acute coronary syndrome.
    Latour-Pérez J
    Ann Pharmacother; 2001 Apr; 35(4):472-9. PubMed ID: 11302412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
    Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke.
    Yang M; Huo X; Miao Z; Wang Y
    Drugs; 2019 Apr; 79(5):515-529. PubMed ID: 30838514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.
    De Luca G; Savonitto S; van't Hof AW; Suryapranata H
    Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncardiac applications of glycoprotein IIb/IIIa inhibitors.
    Almeda FQ; Schaer GL
    Catheter Cardiovasc Interv; 2004 Aug; 62(4):530-8. PubMed ID: 15274167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer therapeutic concept in antiplatelet aggregation inhibition--GPIIb-IIIa receptor antagonists.
    Malhotra S; Mishra NK; Sinha RS; Gupta B
    J Assoc Physicians India; 2000 Mar; 48(3):329-34. PubMed ID: 11229122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients.
    Mak KH; Effron MB; Moliterno DJ
    Drugs Aging; 2000 Mar; 16(3):179-87. PubMed ID: 10803858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors.
    Dobesh PP; Latham KA
    Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.